文献类型：期刊文献

中文题名：脂必泰胶囊治疗血脂异常有效性及安全性的Meta分析

英文题名：A Meta Analysis: the Efficacy and Safety of Zhibitai Capsules in the Treatment of Dyslipidemia

作者：王新强[1];蒋虎刚[1];赵信科[1,2];汪鸣[1];孔珊珊[1];刘苗苗[1];王艳平[1];李应东[1,2]

第一作者：王新强

机构：[1]甘肃中医药大学,兰州730000;[2]甘肃中医药大学附属医院,兰州730020

第一机构：甘肃中医药大学

年份：2021

卷号：37

期号：1

起止页码：193

中文期刊名：中药药理与临床

外文期刊名：Pharmacology and Clinics of Chinese Materia Medica

收录：北大核心:【北大核心2020】；CSCD:【CSCD2021_2022】；

基金：甘肃省中医药循证能力建设项目(编号:2019XZZX-XXG002);甘肃省中医药防治重大疾病科研项目(编号:ZGKZD-2018-02);国家自然科学基金资助项目(编号:81860786)。

语种：中文

中文关键词：脂必泰;血脂异常;Meta分析

外文关键词：Zhibitai;hyperlipidemia;meta-analysis

摘要：目的:评价脂必泰胶囊治疗血脂异常的临床有效性及安全性。方法:计算机检索PubMed、Cochrane library、维普(VIP)、中国知网(CNKI)、万方等数据库建库至2020年6月收录的有关脂必泰联合常规西药治疗血脂异常的随机对照试验(RCTs),并依据纳入排除标准筛选文献,筛选后本研究共纳入19项RCTs,共纳入2148例患者,采用RevMan 5.3软件进行Meta分析。结果:脂必泰联合常规西药在改善总胆固醇(MD=-0.42,95%CI[-0.69,-0.15],P=0.002)、甘油三酯(MD=-0.91,95%CI[-0.41,-0.20],P<0.01)、低密度脂蛋白(MD=-0.28,95%CI[-0.85,-0.14],P=0.01)、高密度脂蛋白(MD=0.81,95%CI[0.06,0.30],P<0.01)、临床总有效率(MD=1.14,95%CI[1.02,1.27],P<0.05)等方面具有显著统计学差异,结果显示脂必泰联合常规西药在改善血脂异常方面均优于单纯西药组。亚组分析结果显示单纯应用脂必泰胶囊较常规西药在改善TC、LDL-L指标无显著优势,对TG、HDL-L指标的改善具有优势。此外,两组都有头疼、胃肠道反应及肝功能异常等不良反应发生,但是试验组与对照组相比,发生不良反应的例数少且症状轻。结论:脂必泰联合常规西药在治疗血脂异常方面具有一定的临床疗效及安全性。
Objective: To evaluate the clinical efficacy and safety of Zhibitai capsules in the treatment of dyslipidemia. Methods: PubMed, Cochrane library, VIP,CNKI,Wanfang and other databases, from the creation of creation to June 2020, were searched for clinical randomized controlled trials of Zhibitai combined with conventional western medicine in the treatment of dyslipidemia. The literature was screened according to the inclusion and exclusion criteria. After screening, a total of 19 clinical randomized controlled trials and 2148 patients were included. The RevMan 5.3 software was used for Meta analysis. Results: Zhibitai combined with conventional western medicine improved the levels of total cholesterol(MD=0.42, 95%CI[0.69,0.15],P=0.002), triglycerides(MD=0.91,95%CI[0.41,0.20],P<0. 01), low density lipoprotein(MD=0.28, 95%CI[0.85,0.14],P=0.01), high density lipoprotein cholesterol(MD=0.81,95%CI) [0.06,0.30],P<0.01),clinical total effective rate(MD=1.14,95% CI[1.02,1.27],P<0.05), with significant statistical differences. The results showed that the improvement effect of Zhibitai combined with conventional western medicine on dyslipidemia was better than that of the western medicine alone. The results of subgroup analysis showed that Zhibitai capsules had no obvious advantages in improving TC and LDL-L compared with the conventional western medicine, but had advantages in improving TG and HDL-L. In addition, patients in both groups had adverse reactions such as headaches, gastrointestinal reactions and liver function abnormalities, but there were fewer cases with adverse reactions and mild symptoms in the test group than in the control group. Conclusion: Zhibitai combined with conventional western medicine has certain clinical efficacy and safety in the treatment of dyslipidemia.